按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
The Lancet Oncologyno. 11 (2024): 1476-1486
WOS
0
0
Regular and Young Investigator Award Abstracts (2024)
0
0
European Journal of Cancer (2024): 113455-113455
WOS
0
0
加载更多
Mark Middleton
教授
Department of Oncology
Medical Sciences Division, University of Oxford;Oxford Cancer and Haematology Centre, University of Oxford
关注
立即认领
分享
关注
立即认领
分享
基本信息
浏览量：299
职业迁徙个人简介
RESEARCH SUMMARY
I’m interested in the development of new drugs to treat cancer, principally immunotherapies. To achieve this I work with scientists and drug companies to validate drug targets, optimise candidate molecules and design both pre-clinical testing programmes and early clinical trials, with the aim of bringing these trials to patients here in Oxford.
I’m interested in the development of new drugs to treat cancer, principally immunotherapies. To achieve this I work with scientists and drug companies to validate drug targets, optimise candidate molecules and design both pre-clinical testing programmes and early clinical trials, with the aim of bringing these trials to patients here in Oxford.
研究兴趣
作者统计
#Papers: 479
#Citation: 22826
H-Index: 66
G-Index: 146
Sociability: 8
Diversity: 3
Activity: 366
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn